Initial pharmacology and toxicology of intravenous desmethylmisonidazole
- 30 April 1982
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 8 (3-4), 371-375
- https://doi.org/10.1016/0360-3016(82)90642-3
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health and Human Services
- National Cancer Institute
This publication has 11 references indexed in Scilit:
- The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508International Journal of Radiation Oncology*Biology*Physics, 1982
- SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical useInternational Journal of Radiation Oncology*Biology*Physics, 1981
- Radiation therapy oncology group clinical trials with misonidazoleCancer, 1981
- Neurotoxicity with desmethylmisonidazoleThe British Journal of Radiology, 1981
- The Pharmacokinetics and Tumor and Neural Tissue Penetrating Properties of SR-2508 and SR-2555 in the Dog-Hydrophilic Radiosensitizers Potentially Less Toxic than MisonidazoleRadiation Research, 1980
- A drug for improved radiosensitization in radiotherapyBritish Journal of Cancer, 1980
- Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicityBritish Journal of Cancer, 1980
- Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizerInternational Journal of Radiation Oncology*Biology*Physics, 1979
- Misonidazole—A drug for trial in radiotherapy and oncologyInternational Journal of Radiation Oncology*Biology*Physics, 1979
- Radiosensitization by Misonidazole (Ro 07-0582) The Importance of Timing and Tumor Concentration of SensitizerRadiation Research, 1978